Document is current
Any future updates will be listed below
-
Authors
Ivashko-Pachima, Yanina
Ganaiem, Maram
Ben-Horin-Hazak, Inbar
Lobyntseva, Alexandra
Bellaiche, Naomi
Fischer, Inbar
Levy, Gilad
Sragovich, Shlomo https://orcid.org/0000-0003-3847-6584
Karmon, Gidon
Giladi, Eliezer
Shazman, Shula
Barak, Boaz https://orcid.org/0000-0001-9724-4578
Gozes, Illana https://orcid.org/0000-0001-9796-2430
-
Funding
Funding for this research was provided by:
European Research Area Network (ERA-NET) Neuron ADNPinMED and Sagol School of Neuroscience Interdisciplinary Partnership Grant (SNIP).
- License Information
-
More Information
Article History
Received: 13 September 2021
Revised: 21 April 2022
Accepted: 26 April 2022
First Online: 10 May 2022
Competing interests
: NAP (CP201, davunetide) use is under patent protection (US patent nos. US7960334, US8618043, and USWO2017130190A1) (IG), PCT/IL2020/051010 (IG) and provisional patent applications (IG inventor and contributing scientists, YI-P, MG, IB-H-H, SS, EG). Davunetide is exclusively licensed to ATED Therapeutics LTD (IG, Co-Founder and Chief Scientific Officer).
